MacKinnon A C, Spedding M, Brown C M
Syntex Research Centre, Heriot-Watt University, Riccarton, Edinburgh, UK.
Trends Pharmacol Sci. 1994 Apr;15(4):119-23. doi: 10.1016/0165-6147(94)90048-5.
The proliferation of receptor subtypes based on differences in amino acid sequence does not necessarily coincide with functional differences. The number of alpha 2-adrenoceptor subtypes, as defined by ligand-binding and molecular studies, has been increasing in the past few years, which suggests the possibility of distinct physiological and pathological pathways that could be targeted by new selective drugs. However, the evidence from functional studies has been less convincing. This could be due to the lack of sufficiently selective ligands or to the similarity between the activated state of receptor subtypes. Species differences and the local receptor environment are also important determinants of the pharmacological profile of a particular subtype. The pharmacology of the putative subtypes of alpha 2-adrenoceptors and their function are discussed in this review by Alison MacKinnon, Mike Spedding and Christine Brown.
基于氨基酸序列差异的受体亚型增殖并不一定与功能差异相一致。过去几年中,通过配体结合和分子研究确定的α2-肾上腺素能受体亚型数量一直在增加,这表明可能存在不同的生理和病理途径,可供新型选择性药物作为靶点。然而,功能研究的证据却不那么令人信服。这可能是由于缺乏足够选择性的配体,或者是受体亚型激活状态之间的相似性所致。物种差异和局部受体环境也是特定亚型药理学特征的重要决定因素。艾莉森·麦金农、迈克·斯佩丁和克里斯汀·布朗在这篇综述中讨论了α2-肾上腺素能受体假定亚型的药理学及其功能。